Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 15, 2019

Primary Completion Date

August 1, 2022

Study Completion Date

March 1, 2023

Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions
RADIATION

Radiotherapy

Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.

Trial Locations (3)

6419 PC

Zuyderland Hospital, Heerlen

6202 AZ

Maastricht University Medical Center, Maastricht

6229 ET

MAATRO clinic, Maastricht

All Listed Sponsors
collaborator

The Netherlands Cancer Institute

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

Zuyderland Medical Centre

OTHER

lead

Maastricht Radiation Oncology

OTHER

NCT03406468 - Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer | Biotech Hunter | Biotech Hunter